Table 3.
Incidence and predictors of hospitalization due to liver injury.a
| Incidence, 1000 person-years (95% CI) | Warfarin: 9.0 (8.3–9.7) | |
| Rivaroxaban: 6.6 (5.7–7.5) | ||
| Apixaban: 5.6 (3.8–7.4) | ||
| Dabigatran: 4.0 (3.2–4.8) | ||
|
| ||
| Predictors of liver injury hospitalization (DOACs versus warfarin) | ||
|
| ||
| Derivation sample | Validation sample | |
| HR (95% CI) | HR (95% CI) | |
|
| ||
| Dabigatran | 0.57 (0.44–0.73) | 0.47 (0.31–0.69) |
|
| ||
| Rivaroxaban | 0.84 (0.69–1.02) | 0.78 (0.59–1.02) |
|
| ||
| Apixaban | 0.74 (0.50–1.08) | 0.49 (0.26–0.93) |
a
Data retrieved from Alonso et al.60
DOACs, direct oral anticoagulants.